BND-35
BND-35 is a novel anti-ILT3 (LILRB4) antagonist antibody developed for the treatment of solid tumors.
BND-35-001 study NCT06274437 is the first-in-human clinical trial of BND-35. It is a Phase 1/2 multicenter, open label, dose escalation and expansion study enrolling advanced cancer patients with select solid tumor types. The study is evaluating the safety and tolerability, maximum tolerated dose/recommended Phase 2 dose (MTD/RP2D), pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of BND-35, administered alone and in combination with an anti-Programmed Cell Death Protein Ligand-1 (PDL-1) or with an anti-Epidermal Growth Factor Receptor (EGFR) antibody. Participants’ tumors and peripheral blood are sampled before treatment and during treatment, to identify and confirm predictive biomarkers to be used in further clinical development.
Following dose escalation and determination of BND-35 recommended Phase 2 dose, the study design allows for the expansion of patient cohorts to evaluate the anti-tumor activity of BND-35 in specific tumor types.
If you are a medical professional and require further information about Biond Biologics, our clinical research, or clinical trials, please send an email to medicalinfo@biondbio.com.